One Lambda, Inc.

One Lambada

Rui Pei

Jar-How Lee

Neng Jen Remi Shih

Thoa Nong

Julie Nguyen

Thao Nong

Described herein are materials and methods for detecting alloantibodies using both HLA and non-HLA antigens in a single assay.

Methods of detecting alloantibodies using HLA and non-HLA antigens

The invention is directed to engineered Fc gamma receptor type III (Fc&#x3b3;II, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Modified Fc gamma receptor type III (FcgammaIII, HNA-1) polypeptides and the uses thereof

The invention is directed to engineered Fc gamma receptor type III (Fc&#x3b3;111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).

Modified Fc gamma receptor type III (FC&#x3b3;III, HNA-1) polypeptides and the uses thereof

The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.

Methods of detecting antibodies specific for denatured HLA antigens

The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.

The present invention provides an improved method for detection of panel reactive antibodies in serum of a subject against HLA class I antigens, which comprises the steps of adding serum from a subject to an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens; incubating the serum and microbeads for sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads; removing the serum components which do not specifically bind with the HLA antigens presented on the microbeads; incubating the microbeads with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens; removing the labeled ligand which is not bound to said HLA antigens; and detecting the presence of labeled ligand bound to said HLA antigens by flow cytometry.

Method for immunobead flow cytometric detection of anti-HLA panel reactive antibody

The present invention provides a kit for the improved method for detection of panel-reactive antibodies in serum of a subject against HLA Class I antigens, which comprises an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens. In the method, serum from a subject is added to said array of microbeads then the mixture is incubated for a sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads. After removing serum components which do not specifically bind with the HLA antigens presented on said microbeads, the microbeads are incubated with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens. The labeled ligand which is not bound to said HLA antigens are removed and the presence of labeled ligand bound to said HLA antigens are detected by flow cytometry.

Growing community of inventors

West Hill, CA, United States of America

Rui Pei